Literature DB >> 10072073

Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.

T Y Nakagawa1, W H Brissette, P D Lira, R J Griffiths, N Petrushova, J Stock, J D McNeish, S E Eastman, E D Howard, S R Clarke, E F Rosloniec, E A Elliott, A Y Rudensky.   

Abstract

Cathepsins have been implicated in the degradation of proteins destined for the MHC class II processing pathway and in the proteolytic removal of invariant chain (Ii), a critical regulator of MHC class II function. Mice lacking the lysosomal cysteine proteinase cathepsin S (catS) demonstrated a profound inhibition of Ii degradation in professional APC in vivo. A marked variation in the generation of MHC class II-bound Ii fragments and presentation of exogenous proteins was observed between B cells, dendritic cells, and macrophages lacking catS. CatS-deficient mice showed diminished susceptibility to collagen-induced arthritis, suggesting a potential therapeutic target for regulation of immune responsiveness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072073     DOI: 10.1016/s1074-7613(00)80021-7

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  101 in total

1.  Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM.

Authors:  J A Villadangos; C Driessen; G P Shi; H A Chapman; H L Ploegh
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

Review 2.  Lysosomal cysteine proteases: facts and opportunities.

Authors:  V Turk; B Turk; D Turk
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

3.  Developmental plasticity of CNS microglia.

Authors:  L Santambrogio; S L Belyanskaya; F R Fischer; B Cipriani; C F Brosnan; P Ricciardi-Castagnoli; L J Stern; J L Strominger; R Riese
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

Review 4.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

5.  Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.

Authors:  Valentina Zavasnik-Bergant; Ana Schweiger; Tadeja Bevec; Rastko Golouh; Vito Turk; Janko Kos
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 6.  Protease signalling: the cutting edge.

Authors:  Boris Turk; Dušan Turk; Vito Turk
Journal:  EMBO J       Date:  2012-02-24       Impact factor: 11.598

7.  Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.

Authors:  Benelita Tina Elie; Vasilena Gocheva; Tanaya Shree; Stacie A Dalrymple; Leslie J Holsinger; Johanna A Joyce
Journal:  Biochimie       Date:  2010-05-04       Impact factor: 4.079

Review 8.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

9.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.

Authors:  Kaoru Saegusa; Naozumi Ishimaru; Kumiko Yanagi; Rieko Arakaki; Kouichi Ogawa; Ichiro Saito; Nobuhiko Katunuma; Yoshio Hayashi
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

10.  Impaired hair follicle morphogenesis and cycling with abnormal epidermal differentiation in nackt mice, a cathepsin L-deficient mutation.

Authors:  Fernando Benavides; Matthew F Starost; Mónica Flores; Irma B Gimenez-Conti; Jean-Louis Guénet; Claudio J Conti
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.